Introduction to Budget-Impact Analysis

Chapter
First Online:

Abstract

This chapter provides an introduction to budget-impact analysis. Because of concerns about rising health-care expenditures, health-care budget holders are interested in estimates of how new health-care interventions will change expenditures or budgets for health systems. Budget-impact analyses develop estimates of these changes with the introduction of the new intervention. These estimates are based on the expected changes in resource use and cost for the mix of interventions and the condition-related outcomes in the population of interest over a given period in the future. Budget-impact analysis differs from cost-effectiveness analysis in perspective, population, interventions compared, time horizon, and outcomes. Many jurisdictions worldwide have developed guidance documents for individuals who perform such analyses and for individuals who review them. Based on these guidelines, we present an overview of the components that should be included in every budget-impact analysis.

Keywords

Budget-impact analysis Cost of medical care Budget-impact analysis guidelines Budget-impact analysis components 
This is a preview of subscription content, log in to check access.

References

  1. Agency for Health Technology Assessment (AHTA). Guidelines for conducting health technology assessment (HTA). Version 2.1. Warsaw: AHTA; 2009.Google Scholar
  2. Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group. National health expenditure (NHE) accounts: NHE summary including share of GDP CY 1960 to 2014. 2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html. Accessed 18 Mar 2016.
  3. Cuyler A. The directory of health economics. 3rd ed. Edward Elgar Publishing; Cheltenham, UK 2014.Google Scholar
  4. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press; Oxford, UK 2015.Google Scholar
  5. Marshall DA, Douglas PR, Drummond MF, Torrance GW, Macleod S, Manti O, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics. 2008;26(6):477–95.CrossRefPubMedGoogle Scholar
  6. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices--budget impact analysis. Value Health. 2007;10(5):336–47.CrossRefPubMedGoogle Scholar
  7. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. 2013. http://nice.org.uk/process/pmg9. Accessed 5 Aug 2016.
  8. Neyt M, Cleemput I, Van de Sande S, Thiry N. Belgian guidelines for budget impact analyses. Acta Clin Belg. 2015;70(3):175–80. doi: 10.1179/2295333714Y.0000000118.CrossRefPubMedGoogle Scholar
  9. Patented Medicine Prices Review Board (PMPRB). Budget impact analysis guidelines: guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. 2007.Google Scholar
  10. Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 4.5. 2015 http://www.pbac.pbs.gov.au/content/information/printable-files/pbacg-book.pdf. Accessed 11 Sep 2015.
  11. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14. doi: 10.1016/j.jval.2013.08.2291.CrossRefPubMedGoogle Scholar
  12. United Nations Department of Economic and Social Affairs. World population ageing: 1950–2050. New York: United Nations; 2001. http://www.un.org/esa/population/publications/worldageing19502050/. Accessed 4 Apr 2016.
  13. WellPoint. Health technology assessment guidelines: drug submission guidelines for new products, new indications, and new formulations. 2008. http://www.pharmamedtechbi.com/~/media/Images/Publications/Archive/The%20Pink%20Sheet/70/043/00700430001/wellpoint_formulary_guidelines.pdf. Accessed 4 Apr 2016.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.RTI Health SolutionsRTI International Research Triangle ParkDurhamUSA

Personalised recommendations